Secondary medical prevention in patients with peripheral arterial disease - Prescriptions of vascular surgeons and medical doctors (angiologists) in a multidisciplinary vascular centre

Vasa - Journal of Vascular Diseases

Volumn 39, Issue 2, 2010, Pages 145-152

  Klein Weigel, Peter Franz ^a   Gutsche Petrak, B ^a   Wolbergs, S ^a   Koning C ^a   Flessenkamper, I ^a  

^a German Red Cross Hospital   (Germany)

Author keywords

Cardiovascular risk factors; Intermittent claudication; Peripheral arterial disease; Quality management; Secondary medical prevention; Secondary prophylaxis

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN II ANTAGONIST; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ANGIOLOGY; ARTERY DISEASE; ARTICLE; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONGESTIVE CARDIOMYOPATHY; DIABETES MELLITUS; ENDARTERECTOMY; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; RETROSPECTIVE STUDY; SECONDARY PREVENTION; SEX DIFFERENCE; SMOKING; SURGEON; VASCULAR SURGERY;

AGED; AGED, 80 AND OVER; ATTITUDE OF HEALTH PERSONNEL; CARDIOVASCULAR AGENTS; COOPERATIVE BEHAVIOR; CRITICAL PATHWAYS; DRUG PRESCRIPTIONS; EVIDENCE-BASED MEDICINE; FEMALE; FEMORAL ARTERY; GERMANY; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HOSPITALIZATION; HUMANS; INTERDISCIPLINARY COMMUNICATION; MALE; PATIENT CARE TEAM; PERIPHERAL VASCULAR DISEASES; PHYSICIAN'S PRACTICE PATTERNS; POPLITEAL ARTERY; PRACTICE GUIDELINES AS TOPIC; RECURRENCE; RETROSPECTIVE STUDIES; SECONDARY PREVENTION; TREATMENT OUTCOME; VASCULAR SURGICAL PROCEDURES;

EID: 77952506263     PISSN: 03011526     EISSN: None     Source Type: Journal    
DOI: 10.1024/0301-1526/a000020     Document Type: Article

References (32)

1. Abuful A, Gidron Y, Henkin Y. Physicians' attitudes toward preventive therapy for coronary artery disease: is there a gender bias? Clin Cardiol 2005; 28: 389-393
2. Al-Omran M, Lindsay TF, Major J, Jawas A, Leiter LA, Verma S; Systematic Assessment of Vascular Risk Investigators. Perceptions of Canadian vascular surgeons toward pharmacological risk reduction in patients with peripheral arterial disease. Ann Vasc Surg 2006; 20: 555-563
3. Al-Omran M. Knowledge and attitude of physicians in a major teaching hospital towards atherosclerotic risk reduction therapy in patients with peripheral arterial disease. Vasc Health Risk Manag 2007; 3: 1019-1027
4. Anand SS, Kundi A, Eikelboom J, Yusuf S. Low rates of preventive practices in patients with peripheral vascular disease. Can J Cardiol 1999; 15: 1259-1263 (Pubitemid 30006765)
5. Antiplatelet Trialists' Collaboration Collaborative overview of randomised trials of anti-platelet therapy: Prevention of death, myocardial infarction, and stroke by prolonged anti-platelet therapy in various categories of patients. BMJ 1994; 308: 81-106. Erratum in: BMJ 1994; 308: 1540.
6. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324: 71-86. Erratum in: BMJ 2002; 324: 141.
7. Belch JJ, Topol EJ, Agnelli G, Bertrand M, Califf RM, Clement DL, Creager MA, Easton JD, Gavin JR 3rd, Greenland P, Hankey G, Hanrath P, Hirsch AT, Meyer J, Smith SC, Sullivan F, Weber MA; Prevention of Atherothrombotic Disease Network. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med 2003; 163: 884-892
8. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, Goto S, Liau CS, Richard AJ, Röther J, Wilson PW; REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in'outpatients with atherothrombosis. JAMA 2006; 295: 180-189 (Pubitemid 43076437)
9. Bianchi C, Montalvo V, Ou HW, Bishop V, Abou-Zamzam AM Jr. Pharmacologic risk factor treatment of peripheral arterial disease is lacking and requires vascular surgeon participation. Ann Vasc Surg 2007; 21: 163-166 (Pubitemid 46367551)
10. Burns P, Lima E, Bradbury AW. Second best medical therapy. Eur J Vasc Endovasc Surg. 2002; 24: 400-404
11. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, Rubin HR. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999; 282: 1458-1465
12. Cacoub PP, Abola MT, Baumgartner I, Bhatt DL, Creager MA, Liau CS, Goto S, Röther J, Steg PG, Hirsch AT; on behalf of the REACH Registry Investigators. Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Atherosclerosis. 2008; Oct 31. [Epub ahead of print]
13. Campbell NC. Secondary prevention clinics: improving quality of life and outcome.Heart. 2004; 90 Suppl 4: iv29-32.
14. Cassar K, Belch JJ, Brittenden J. Are national cardiac guidelines being applied by vascular surgeons? Eur J Vasc Endovasc Surg 2003; 26: 623-628
15. Cho L, Hoogwerf B, Huang J, Brennan DM, Hazen SL. Gender differences in utilization of effective cardiovascular secondary prevention: a Cleveland clinic prevention database study. J Womens Health 2008; 17: 515-521 (Pubitemid 351674102)
16. Coppola G, Novo S. Statins and peripheral arterial disease: effects on claudication, disease progression, and prevention of cardiovascular events. Arch Med Res 2007; 38: 479-488 (Pubitemid 46873814)
17. Delaney EK, Murchie P, Lee AJ, Ritchie LD, Campbell NC. Secondary prevention clinics for coronary heart disease: a 10-year follow-up of a randomised controlled trial in primary care. Heart 2008; 94: 1419-1423
18. Eckstein HH, Niedermeier HP, Noppeney T, Umscheid T, Wenk H, Imig H. Certification of vascular centers - a project of the German Society for Vascular Surgery. Eur J Vasc Endovasc Surg 2006; 32: 279-285 (Pubitemid 44226070)
19. Erez G, Leitersdorf E. The rationale for using HMG-CoA reductase inhibitors ('statins') in peripheral arterial disease. Eur J Vasc Endovasc Surg 2007; 33: 192-201. (Pubitemid 46090501)
20. Gasse C, Jacobsen J, Larsen AC, Schmidt EB, Johannesen NL, Videbaek J, Sørensen HT, Johnsen SP. Secondary medical prevention among Danish patients hospitalised with either peripheral arterial disease or myocardial infarction. Eur J Vasc Endovasc Surg 2008; 35: 51-58 (Pubitemid 350245449)
21. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R,Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, Herrmann-Lingen C, Hoes A, Humphries S, Knapton M, Perk J, Priori SG, Pyorala K, Reiner Z, Ruilope L, Sans-Menendez S, Op Reimer WS, Weissberg P, Wood D, Yarnell J, Zamorano JL, Walma E, Fitzgerald T, Cooney MT, Dudina A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Funck-Brentano C, Filippatos G, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Altiner A, Bonora E, Durrington PN, Fagard R, Giampaoli S, Hemingway H, Hakansson J, Kjeldsen SE, Larsen L, Mancia G, Manolis AJ, Orth-Gomer K, Pedersen T, Rayner M, Ryden L, Sammut M, Schneiderman N, Stalenhoef AF, Tokgözoglu L, Wiklund O, Zampelas A; European Society of Cardiology (ESC); European Association for Cardiovascular Prevention and Rehabilitation (EACPR); Council on Cardiovascular Nursing; European Association for Study of Diabetes (EASD); International Diabetes Federation Europe (IDF-Europe); European Stroke Initiative (EUSI); Society of Behavioural Medicine (ISBM); European Society of Hypertension (ESH); WONCA Europe(European Society of General Practice / Family Medicine); European Heart Network (EHN); European Atherosclerosis Society (EAS). European guidelines oncardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007; 14 Suppl 2: S1-113.
22. Greco PJ, Eisenberg JM. Changing physicians' practices. N Engl J Med 1993; 329: 1271-1273
23. Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg 2007; 45: 645-654
24. Kahn S, Flather M, Mister R, Delahunty N, Fowkes G, Bradbury G, stansby G. characteristics and treatments of patients with peripheral arterial disease referred to UK Vascular Clinics: results of a prospective registry. Eur J Vasc Endovasc Surg 2007; 33: 442-450
25. Lee HY, Cooke CE, Robertson TA. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge. J Manag Care Pharm 2008; 14: 271-280 (Pubitemid 351711978)
26. No authors listed. Joint British recommendations on prevention of coronary heart disease in clinical practice: summary. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association. BMJ 2000; 320: 705-8. Erratum in: BMJ 2001; 323: 780.
27. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG; TASC II Working Group, Bell K, Caporusso J, Durand-Zaleski I, Komori K, Lammer J, Liapis C, Novo S, Razavi M, Robbs J, Schaper N, Shigematsu H, Sapoval M, White C, White J, Clement D, Creager M, Jaff M, Mohler E 3rd, Rutherford RB, Sheehan P, Sillesen H, Rosenfield K. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 2007; 33 Suppl 1: S1-75.
28. Schouten O, Welten GM, Bax JJ, Poldermans D. Re: Secondary medical prevention in patients with peripheral arterial disease. Eur J Vasc Endovasc Surg 2008; 35: 59-60. (Pubitemid 350235222)
29. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA; AHA/ACC; National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006; 113: 2363-72. Erratum in: Circulation; 113: e847.
30. Vohra RS, Gough MJ, Homer-Vanniasinkam S, Mavor AI, Howell S. Secondary prevention in patients with peripheral arterial disease: are we letting ourpatients down? Eur J Vasc Endovasc Surg 2007; 33: 190-191
31. Weiss N, Bergert H. Structured surveillance of patients with peripheral arterial occlusive disease after peripheral vascular interventions. VASA 2009; 38: in press.
32. Youssef F, Gupta P, Mikhailidis DP, Hamilton G. Risk modification in patients with peripheral arterial disease: a retrospective survey. Angiology 2005; 56: 279-287 (Pubitemid 40656430)